Valsalva retinopathy in pregnancy. Should we treat?
نویسندگان
چکیده
منابع مشابه
Valsalva retinopathy in pregnancy. Should we treat?
A 26-year-old Caucasian woman at 37 weeks gestation presented to the eye casualty with a sudden history of reduced vision and floaters in the left eye following an episode of sneezing. Her visual acuity was 6/6 and 6/60 in her right and left eyes, respectively. Anterior segment examination was unremarkable. Pupil reactions were normal. Fundus examination of the right eye was normal. Fundus exam...
متن کاملValsalva retinopathy in pregnancy: a case report
Introduction: Valsalva retinopathy is a unilateral or bilateral condition that occurs when increased intra-thoracic or intra-abdominal pressure transmitted to the eye causes a sharp rise in the intraocular venous pressure, and rupture of superficial retinal capillaries. The patient often gives a history of a recent strenuous physical act, which could have increased the intra-thoracic pressure. ...
متن کاملShould we treat tuberculin converters.
Should we or should we not treat primary tuberculosis? Answers to this question have gone from one extreme, that we should treat them all with preventorium care, to the other extreme, that none of them should be treated because those who had sanitorium care did no better than those who had none. Now that we have antituberculous drugs of relatively low toxicity, this same question has come up ag...
متن کاملShould We Treat Prehypertension in Diabetes?
E levated blood pressure (BP), even within the normal range, is associated with cardiovascular (CV) morbidity and mortality. Therefore, the Joint National Committee (JNC) VII introduced the term “prehypertension” in the general population, which is defined as BP levels of 120–139 mmHg and 80–89 mmHg for systolic and diastolic BP, respectively (1). Prehypertension includes two different categori...
متن کامل“How should we treat older patients with Metastatic Colorectal Cancer, A Review”
Nearly 50 % of newly diagnosed colorectal cancer, affect people over 70 years of age. Inclusion of older patients in clinical trials has been extremely rare. As a result, there is debate on how to manage these patients because it is still unclear how to balance the therapeutic advantages and toxicities. For patients who do not have comorbid conditions, with performance status (P.S.) 0–1, treatm...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JRSM Short Reports
سال: 2011
ISSN: 2042-5333
DOI: 10.1258/shorts.2011.011035